Elevance Health, Inc. $ELV Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 6.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,176 shares of the company’s stock after purchasing an additional 2,686 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Elevance Health were worth $14,785,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. PDS Planning Inc lifted its position in Elevance Health by 3.4% during the fourth quarter. PDS Planning Inc now owns 1,898 shares of the company’s stock valued at $665,000 after purchasing an additional 62 shares during the period. Parcion Private Wealth LLC acquired a new position in Elevance Health during the fourth quarter valued at $258,000. CWM LLC lifted its position in Elevance Health by 2.1% during the fourth quarter. CWM LLC now owns 19,482 shares of the company’s stock valued at $6,829,000 after purchasing an additional 394 shares during the period. Towne Trust Company N.A increased its holdings in Elevance Health by 4.0% in the fourth quarter. Towne Trust Company N.A now owns 3,002 shares of the company’s stock valued at $1,052,000 after buying an additional 115 shares in the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its holdings in Elevance Health by 22.2% in the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,100 shares of the company’s stock valued at $386,000 after buying an additional 200 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Stock Up 2.3%

ELV stock opened at $323.02 on Friday. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $432.93. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm has a 50-day simple moving average of $308.99 and a 200-day simple moving average of $331.91. The stock has a market capitalization of $70.95 billion, a P/E ratio of 12.86, a P/E/G ratio of 1.74 and a beta of 0.49.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. During the same quarter in the prior year, the firm earned $3.84 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were given a dividend of $1.72 per share. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date was Tuesday, March 10th. This represents a $6.88 annualized dividend and a dividend yield of 2.1%. Elevance Health’s payout ratio is currently 27.39%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Guggenheim cut their price objective on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a report on Thursday, January 29th. Truist Financial cut their price objective on shares of Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a report on Monday, April 13th. Evercore assumed coverage on shares of Elevance Health in a report on Wednesday, April 8th. They issued a “hold” rating and a $345.00 price objective for the company. Sanford C. Bernstein cut their price objective on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a report on Thursday, January 29th. Twelve equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $383.57.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.